Daisuke Shibahara

Daisuke Shibahara

Auto-generated profile, based on publicly available information

Daisuke Shibahara

Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
YKYukie Kashima
Yukie Kashima
DSDaisuke Shibahara
Daisuke Shibahara
ASAyako Suzuki
Ayako Suzuki
KMKyoko Muto
Kyoko Muto
IKIkei S. Kobayashi
Ikei S. Kobayashi
SKSusumu Kobayashi
Susumu Kobayashi
Tumor heterogeneity underlies resistance to tyrosine kinase inhibitors (TKI) in lung cancers harboring EGFR mutations. Previous evidence suggested that subsets of preexisting resistant cells are selected by EGFR-TKI treatment, or alternatively, that diverse acquired resistance mechanisms emerge from drug-tolerant persister (DTP) cells. Many studies have used bulk tumor specimens or subcloned resistant cell lines to identify resistance mechanism. However, intratumoral heterogeneity can result in divergent responses to therapies, requiring additional approaches to reveal the complete spectrum of resistance mechanisms. Using EGFR-TKI-resistant cell models and clinical specimens, we performed single-cell RNA-seq and single-cell ATAC-seq analyses to define the transcriptional and epigenetic landscape of parental cells, DTPs, and tumor cells in a fully resistant state. In addition to AURKA, VIM, and AXL, which are all known to induce EGFR-TKI resistance, CD74 was identified as a novel gene that plays a critical role in the drug-tolerant state. In vitro and in vivo experiments demonstrated that CD74 upregulation confers resistance to the EGFR-TKI osimertinib and blocks apoptosis, enabling tumor regrowth. Overall, this study provides new insight into the mechanisms underlying resistance to EGFR-TKIs. Significance: Single-cell analyses identify diverse mechanisms of resistance as well as the state of tolerant cells that give rise to resistance to EGFR tyrosine kinase inhibitors.

3 July 2024 in Clinical Lung Cancer
Verified
Journal Article
Open access
DSDaisuke Shibahara
Daisuke Shibahara
KTKentaro Tanaka
Kentaro Tanaka
OTOsamu Togao
Osamu Togao
YSYoshimasa Shiraishi
Yoshimasa Shiraishi
YYYasuto Yoneshima
Yasuto Yoneshima
IOIsamu Okamoto
Isamu Okamoto

25 March 2024 in Thoracic Cancer
Verified
Journal Article
Open access
YYYoshihiro Yamamoto
Yoshihiro Yamamoto
DSDaisuke Shibahara
Daisuke Shibahara
TMTaro Mori
Taro Mori
KOKohei Otsubo
Kohei Otsubo
YSYoshimasa Shiraishi
Yoshimasa Shiraishi
IOIsamu Okamoto
Isamu Okamoto
Tracheomediastinal fistula is a rare but life‐threatening complication of cancer. We report a case of tracheomediastinal fistula induced by concurrent chemoradiotherapy in limited stage small cell lung cancer. Despite the treatment response, the metastatic paratracheal lymph node increased gradually during concurrent chemoradiotherapy, resulting in the occurrence of tracheomediastinal fistula and mediastinitis. Without any surgical intervention, the patient achieved successful recovery from mediastinitis through antibiotic treatment, although the tracheomediastinal fistula remained open. In this report, we also review previous studies of tracheomediastinal and bronchomediastinal fistulas and summarize the clinical features.

13 February 2025 in bioRxiv
Verified
Preprint
Open access
SNSatoshi Nakamura
Satoshi Nakamura
DSDaisuke Shibahara
Daisuke Shibahara
KTKentaro Tanaka
Kentaro Tanaka
YKYasuyuki Kishikawa
Yasuyuki Kishikawa
MHMikiko Hashisako
Mikiko Hashisako
IOIsamu Okamoto
Isamu Okamoto
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) provide therapeutic benefit in EGFR mutation–positive non–small cell lung cancer, but some individuals develop early resistance. We performed spatial transcriptomics analysis of pre- and posttreatment tumor samples from the same patients to explore the underlying mechanisms of such early resistance. The proportion and activation of fibroblasts increased in association with the development of early resistance, whereas a distinct tumor cell cluster showed activation of tumor necrosis factor–α signaling via the NF-κB pathway even before treatment. Also in the early resistance sample, specific tumor cell clusters interacted with immune and stromal cells. Immature tertiary lymphoid structures (TLSs) were enriched in the early resistance sample, whereas mature TLSs were observed in the long-term response sample. These findings implicate tumor heterogeneity and an inflammatory tumor microenvironment in early EGFR-TKI resistance, providing insight into potential therapeutic strategies to improve treatment outcomes.

24 December 2020 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
MFMakoto Furugen
Makoto Furugen
DSDaisuke Shibahara
Daisuke Shibahara
TKTomo Kiyuna
Tomo Kiyuna
WKWakaki Kami
Wakaki Kami
KMKazuya Miyagi
Kazuya Miyagi
JFJiro Fujita
Jiro Fujita
Pemetrexed has significant efficacy for some non‐squamous non‐small cell lung cancer cases, as demonstrated in the current case. For those patients, pemetrexed administration should be carefully considered.

31 March 2023
Verified
Other
Open access
YKYukie Kashima
Yukie Kashima
DSDaisuke Shibahara
Daisuke Shibahara
ASAyako Suzuki
Ayako Suzuki
KMKyoko Muto
Kyoko Muto
IKIkei S. Kobayashi
Ikei S. Kobayashi
SKSusumu Kobayashi
Susumu Kobayashi
Tumor heterogeneity underlies resistance to tyrosine kinase inhibitors (TKI) in lung cancers harboring EGFR mutations. Previous evidence suggested that subsets of preexisting resistant cells are selected by EGFR-TKI treatment, or alternatively, that diverse acquired resistance mechanisms emerge from drug-tolerant persister (DTP) cells. Many studies have used bulk tumor specimens or subcloned resistant cell lines to identify resistance mechanism. However, intratumoral heterogeneity can result in divergent responses to therapies, requiring additional approaches to reveal the complete spectrum of resistance mechanisms. Using EGFR-TKI-resistant cell models and clinical specimens, we performed single-cell RNA-seq and single-cell ATAC-seq analyses to define the transcriptional and epigenetic landscape of parental cells, DTPs, and tumor cells in a fully resistant state. In addition to AURKA, VIM, and AXL, which are all known to induce EGFR-TKI resistance, CD74 was identified as a novel gene that plays a critical role in the drug-tolerant state. In vitro and in vivo experiments demonstrated that CD74 upregulation confers resistance to the EGFR-TKI osimertinib and blocks apoptosis, enabling tumor regrowth. Overall, this study provides new insight into the mechanisms underlying resistance to EGFR-TKIs.Significance:Single-cell analyses identify diverse mechanisms of resistance as well as the state of tolerant cells that give rise to resistance to EGFR tyrosine kinase inhibitors.